Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells (2023)

Peer-Reviewed Study · Semkova S, Nikolova B, Tsoneva I, Antov G, Ivanova D, Angelov A, Zhelev Z, Bakalova R · March 2023

Semkova S et al., 2023-03: Fenbendazole for 48 h produced oxidative stress and reduced viability preferentially in highly metastatic triple-negative MDA-MB-231 breast cancer cells compared with MCF-7 and normal MCF-10A cells.

The data demonstrated that MDA-MB-231 cells were more vulnerable to fenbendazole-induced oxidative stress than MCF-7 cells.

Semkova S et al., 2023-03: Fenbendazole for 48 h produced oxidative stress and reduced viability preferentially in highly metastatic triple-negative MDA-MB-231 breast cancer cells compared with MCF-7 and normal MCF-10A cells. C2/C3 Semkova 2023. Study type: in vitro (MCF-10A normal, MCF-7 luminal, MDA-MB-231 triple-negative); N/A; country Bulgaria (Bulgarian Academy of Sciences, Sofia); dose not stated in abstract, 48-h exposure; funder: not listed; conflicts: none declared; maker: not stated; comparators: normal breast epithelial cells and low-metastatic MCF-7. Study type: lab.